News for Connect Biopharma Holdings Limited (CNTB)

Northland's analyst, Carl Byrnes, has initiated coverage on Connect Biopharma (CNTB), recommending it with an Outperform rating and setting a price target of $7

Northland has started its coverage on Connect Biopharma (CNTB), assigning it an Outperform rating. The firm has set a target price of $7.50 for the stock, refle

”“ Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding co

- Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformation and growth -

Connect Biopharma (CNTB) to terminate ADR program, switching to direct Nasdaq listing on September 2, 2025. ADRs will be exchanged for ordinary shares at a

SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ('Connect Biopharma” or the 'Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it plans to terminate the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank Trust Company Americas (the 'Depositary”), and the holders and beneficial owners of American Depositary Shares ('ADSs”) evidenced by American Depositary Receipts ('ADRs”) issued thereunder (the 'Deposit Agreement”).

Connect Biopharma (NASDAQ:CNTB) to participate in the BTIG Virtual Biotechnology Conference on July 29, 2025. Investors can access the live webcast thro

Connect Biopharma (CNTB) has successfully met the minimum bid price requirement set by Nasdaq under its Listing Rule 5450(a)(1). The company announced that on J

Connect Biopharma (CNTB) regains compliance with Nasdaq's minimum bid price requirement. Company's shares maintained a minimum closing bid price of $1.0

Simcere Pharmaceutical, a partner of Connect Biopharma (CNTB), has submitted a New Drug Application (NDA) in China for rademikibart, targeting atopic derma

Connect Biopharma (CNTB) has reported that its Chinese partner, Simcere Pharmaceutical, has filed a New Drug Application (NDA) with China's National Medical Pro

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited ( CNTB) (”œConnect Biopharma”, ”œConnect”, or the ”œCompany”), a clin

**media[654124]**

Connect Biopharma (CNTB) has announced the filing of a mixed securities shelf totaling $300 million. This strategic move allows the company to potentially offer

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited ( CNTB) (”œConnect Biopharma” or the ”œCompany”), a clinical-stage bioph

**media[639375]**

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to devel

In the first quarter of 2025, Connect Biopharma (CNTB) made significant progress, marked by a successful Type C meeting with the U.S. FDA and the publication of

Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and CO